| # | Title | Journal | Year | Citations |
|---|
| 1 | Epidemiology of Brain Metastases | Current Oncology Reports | 2012 | 975 |
| 2 | The Obesity Paradox in Cancer: a Review | Current Oncology Reports | 2016 | 386 |
| 3 | Obesity and Cancer Risk: Recent Review and Evidence | Current Oncology Reports | 2011 | 371 |
| 4 | Updates on Management of Gastric Cancer | Current Oncology Reports | 2019 | 292 |
| 5 | The role of C-reactive protein as a prognostic indicator in advanced cancer | Current Oncology Reports | 2002 | 268 |
| 6 | The Gut Microbiome and Obesity | Current Oncology Reports | 2016 | 230 |
| 7 | HIF Inhibitors: Status of Current Clinical Development | Current Oncology Reports | 2019 | 230 |
| 8 | Perifosine: Update on a novel Akt inhibitor | Current Oncology Reports | 2009 | 221 |
| 9 | COVID-19 and Cancer: a Comprehensive Review | Current Oncology Reports | 2020 | 220 |
| 10 | Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides | Current Oncology Reports | 2004 | 201 |
| 11 | Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls | Current Oncology Reports | 2020 | 199 |
| 12 | Cancer-Promoting Effects of Microbial Dysbiosis | Current Oncology Reports | 2014 | 197 |
| 13 | Integrins: Molecular targets in cancer therapy | Current Oncology Reports | 2006 | 196 |
| 14 | Pazopanib: A novel multitargeted tyrosine kinase inhibitor | Current Oncology Reports | 2007 | 191 |
| 15 | VEGF Inhibition, Hypertension, and Renal Toxicity | Current Oncology Reports | 2012 | 187 |
| 16 | The Impact of Obesity on Breast Cancer Diagnosis and Treatment | Current Oncology Reports | 2019 | 187 |
| 17 | PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies | Current Oncology Reports | 2012 | 175 |
| 18 | Melanoma and the tumor microenvironment | Current Oncology Reports | 2008 | 173 |
| 19 | Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma | Current Oncology Reports | 2013 | 155 |
| 20 | Emerging Variants of Castration-Resistant Prostate Cancer | Current Oncology Reports | 2017 | 150 |
| 21 | VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy | Current Oncology Reports | 2009 | 139 |
| 22 | Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management | Current Oncology Reports | 2012 | 138 |
| 23 | Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: Rationale and Implications | Current Oncology Reports | 2019 | 138 |
| 24 | Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy | Current Oncology Reports | 2010 | 133 |
| 25 | Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management | Current Oncology Reports | 2014 | 133 |
| 26 | Immunotherapy for Head and Neck Squamous Cell Carcinoma | Current Oncology Reports | 2018 | 131 |
| 27 | Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? | Current Oncology Reports | 2021 | 131 |
| 28 | Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention | Current Oncology Reports | 2001 | 128 |
| 29 | Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials) | Current Oncology Reports | 2016 | 128 |
| 30 | CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions | Current Oncology Reports | 2019 | 122 |
| 31 | PI3K Inhibitors in Breast Cancer Therapy | Current Oncology Reports | 2019 | 120 |
| 32 | c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy | Current Oncology Reports | 2007 | 119 |
| 33 | Physical Activity and Cancer | Current Oncology Reports | 2012 | 119 |
| 34 | Telemedicine and Palliative Care: an Increasing Role in Supportive Oncology | Current Oncology Reports | 2017 | 119 |
| 35 | The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe | Current Oncology Reports | 2018 | 119 |
| 36 | Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status | Current Oncology Reports | 2011 | 115 |
| 37 | Neurologic Complications of Cancer and its Treatment | Current Oncology Reports | 2010 | 114 |
| 38 | Radionuclide Therapy for Neuroendocrine Tumors | Current Oncology Reports | 2017 | 113 |
| 39 | Clinical Implications of Sarcopenic Obesity in Cancer | Current Oncology Reports | 2016 | 111 |
| 40 | Mucosal Melanoma: a Literature Review | Current Oncology Reports | 2018 | 111 |
| 41 | Molecular Subtypes of Bladder Cancer | Current Oncology Reports | 2018 | 111 |
| 42 | Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors | Current Oncology Reports | 2009 | 110 |
| 43 | A Re-evaluation of the “Oncogenic” Nature of Wnt/β-catenin Signaling in Melanoma and Other Cancers | Current Oncology Reports | 2010 | 110 |
| 44 | Advances in the Treatment of Malignant Gliomas | Current Oncology Reports | 2010 | 107 |
| 45 | Differentiating agents in pediatric malignancies: Retinoids in neuroblastoma | Current Oncology Reports | 2000 | 106 |
| 46 | Angiozyme: A Novel angiogenesis inhibitor | Current Oncology Reports | 2001 | 106 |
| 47 | Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 | Current Oncology Reports | 2017 | 106 |
| 48 | The chemokine receptors CXCR4 and CXCR3 in cancer | Current Oncology Reports | 2009 | 105 |
| 49 | How Sunlight Causes Melanoma | Current Oncology Reports | 2010 | 104 |
| 50 | Mechanisms of Therapeutic Resistance in Prostate Cancer | Current Oncology Reports | 2017 | 103 |
